• Explore /
  • Poster
  • / Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.

Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.

Abstract Poster

Authors

null

Ignacio Gil-Bazo

Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain

Ignacio Gil-Bazo , Ainhoa Castillo , Maria E. Zudaire , Estefania Arevalo , Omar Esteban Carranza , Juan Pablo Fusco , Eduardo Castanon , Jose Luis Perez-Gracia , José María López-Picazo , Alfonso Gurpide , Jesus Garcia-Foncillas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Citation

J Clin Oncol 30, 2012 (suppl 5; abstr 145)

DOI

10.1200/jco.2012.30.5_suppl.145

Abstract #

145

Poster Bd #

D8

Abstract Disclosures

Similar Posters

First Author: Sumit Kumar Subudhi

First Author: Adam Kessel

First Author: Manish Kohli

First Author: Victoria J. Sinibaldi